EP0975610A1 - Tripeptide and tetrapeptide pharmaceutical compounds - Google Patents

Tripeptide and tetrapeptide pharmaceutical compounds

Info

Publication number
EP0975610A1
EP0975610A1 EP98907625A EP98907625A EP0975610A1 EP 0975610 A1 EP0975610 A1 EP 0975610A1 EP 98907625 A EP98907625 A EP 98907625A EP 98907625 A EP98907625 A EP 98907625A EP 0975610 A1 EP0975610 A1 EP 0975610A1
Authority
EP
European Patent Office
Prior art keywords
compound
hydrogen
group
methyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98907625A
Other languages
German (de)
French (fr)
Other versions
EP0975610A4 (en
Inventor
Bryan H. Norman
Chuan Shih
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawaii
Wayne State University
Eli Lilly and Co
Original Assignee
University of Hawaii
Wayne State University
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hawaii, Wayne State University, Eli Lilly and Co filed Critical University of Hawaii
Publication of EP0975610A1 publication Critical patent/EP0975610A1/en
Publication of EP0975610A4 publication Critical patent/EP0975610A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention relates to novel cryptophycin compounds useful as anti-microtubule agents.
  • Neoplastic diseases characterized by the proliferation of cells not subject to the normal control of cell growth, are a major cause of death in humans and other mammals.
  • Clinical experience in cancer chemotherapy has demonstrated that new and more effective drugs are desirable to treat these diseases.
  • Such clinical experience has also demonstrated that drugs which disrupt the microtubule system of the cytoskeleton can be effective in inhibiting the proliferation of neoplastic cells.
  • the presently claimed compounds having an amide substitution in the cryptophycin ring, have surprisingly potent antimicrotuble activity while further having especially desired solubility properties.
  • the compounds claimed herein address the need for compounds having acceptable solubility while retaining the desired antimicrotuble activity.
  • Such agents having the ability to disrupt the microtubule system can be useful for research purposes.
  • the presently claimed invention provides novel cryptophycin compounds of Formula I
  • Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, substituted aromatic, unsubstituted heteroaromatic, and substituted heteroaromatic group;
  • R 1 is selected from the group consisting of halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, and phosphate;
  • R 2 is OH or SH; or
  • R 1 and R 2 may be taken together with Ci ⁇ and Cig to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, or monoalkylphosphate ring; or R 1 and R 2 may be taken together to form a second bond between Ci ⁇ and Cig;
  • R 3 is a lower alkyl group
  • R 4 is H or H 2
  • R 5 is H or H 2 ;
  • R 4 and R 5 may be taken together to form a second bond between C 13 and C 14 ;
  • R 6 is selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, and dihaloalkoxybenzyl group;
  • R 7 is H or a lower alkyl group;
  • R 8 is H or a lower alkyl group;
  • R 7 and R 8 may optionally be taken together to form a cyclopropyl ring
  • R 9 is selected from the group consisting of H, a lower alkyl group, (C 1 -C 3 ) alkylaryl, and aryl;
  • R 10 is selected from the group consisting of H, a lower alkyl group, (C 1 -C 3 ) alkylaryl, and aryl;
  • R 11 is selected from the group consisting of hydrogen, simple alkyl, OH, phenyl, substituted phenyl, benzyl, and substituted benzyl;
  • X is 0, NH or alkylamino; or a pharmaceutically acceptable salt or solvate thereof.
  • the present invention provides pharmaceutical formulations, a method for disrupting a microtubulin system using an effective amount of a compound of Formula I, a method for inhibiting the proliferation of mammalian cells comprising administering an effective amount of a compound of Formula I, and a method for treating neoplasia in a mammal comprising administering an effective amount of a compound of Formula I.
  • the term "simple alkyl” shall refer to C 1 -C 7 alkyl wherein the alkyl may be saturated, unsaturated, branched, or straight chain. Examples include, but are in no way limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, propenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, methylated pentyl groups and the like.
  • substituted phenyl shall refer to a phenyl group with from one to three non- hydrocarbon substituents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I.
  • substituted benzyl shall refer to a benzyl group with from one to three non- hydrocarbon substitutents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I .
  • Lower alkoxyl group means any alkyl group of one to five carbon atoms bonded to an oxygen atom.
  • lower alkyl group means an alkyl group of one to five carbons and includes linear and nonlinear hydrocarbon chains, including for example, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, and methylated pentyl groups.
  • allylically substituted alkene means any alkene having from one to seven carbon atoms which contains an alkyl substitution on it.
  • epoxide ring means a three- membered ring whose backbone consists of two carbons and an oxygen atom.
  • aziridine ring means a three-membered ring whose backbone consists of two carbon atoms and a nitrogen atom.
  • sulfide ring means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom.
  • episulfide ring menas a three-membered ring whos backbone consists of two carbon and a sulfur atom.
  • sulfate group menas a five membered ring consisting of a carbon- carbon-oxygen-sulfur-oxygen backbone with two additional oxygen atoms connected to the sulfur atom.
  • monoalkylphosphate ring means a five membered ring consisting of a carbon-carbon-oxygen-phosphorous-oxygen backbone with two additional oxygen atoms, one of which bears a lower alkyl group, connected to the phosphorous atom.
  • “simple unsubstituted aromatic group” refers to common aromatic rings having 4n+2 electrons in a moncyclic conjugated system, for example, but not limited to: furyl, pyrrolyl, thienyl, pyridyl and the like, or a bicyclic conjugated system, for example but not limited to indolyl or naphthyl .
  • “simple substituted aromatic group” refers to a phenyl group substituted with a single group selected from the group consisting of halogen and lower alkyl group.
  • aryl means an organic radical derived from an aromatic hydrocarbon by the removal of one atom; e.g., phenyl or naphthyl . Most preferably, aryl refers to C 6 ⁇ C ⁇ o aryl, wherein the aryl ring system, including any alkyl substitutions, comprises from 6 to 10 carbon atoms.
  • C 1 -C 3 alkylaryl represents an (C 1 -C 3 ) alkylaryl substituent wherein the alkyl group is linear, such as but not limited to, benzyl, phenethyl, 3- phenylpropyl, or phenyl- t-butyl; or branched.
  • the alkylaryl moitety is attached to the parent nucleus via the alkyl group .
  • alkylamino has its common meaning. Thus, the phrase refers to N-R RI wherein R RI is C 1 -C 3 alkyl.
  • R RI is C 1 -C 3 alkyl.
  • heteromatic group refers to aromatic rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur.
  • halogen refers to those members of the group on the periodic table historically known as halogens. Methods of halogenation include, but are not limited to, the addition of hydrogen halides, substitution at high temperature, photohalogenation, etc., and such methods are known to the skilled artisan.
  • the term “mammal” shall refer to the Mammalia class of higher vertebrates.
  • the term “mammal” includes, but is not limited to, a human.
  • the term “treating” as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
  • the cryptophycin compounds claimed herein can be useful for vetrinary health purposes as well as for the treatment of a human patient.
  • R 8 is ethyl, propyl, isopropyl, butyl, isobutyl or isopentyl;
  • R 7 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, or isopentyl; C) R 7 is H, R 8 is methyl, R 3 is methyl, and X and
  • Y are not both 0;
  • R 3 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl;
  • R 9 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyl;
  • R 10 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyl;
  • G a cryptophycin compound wherein at least one of the groups selected from the group consisting of C-3, C-6, C-7, C-10, C-16, C-17, and C-18 has R stereochemistry (numbering as set forth in claim 1 i nfra . ) ;
  • H a cryptophycin compound wherein at least one of the " groups selected from the group consisting of C-3, C-6, C-7, C-10, C-16, C-17, and C-18 has S stereochemistry (numbering as set forth in claim 1 i nfra . ) ;
  • Ar is phenyl with a substituent selected from the group consisting of hydrogen, halogen, and simple alkyl;
  • R 7 and R 8 are each selected from hydrogen or
  • R 11 is simple alkyl
  • R is selected from the group consisting of methyl, ethyl, n-propyl, and phenyl;
  • R 1 and R 2 form an epoxide ring
  • R 4 and R 5 form a double bond
  • R 6 is substituted benzyl wherein one substituent is a halogen and one is an OR 12 group wherein R 12 is lower alkyl;
  • W a compound wherein Y is selected from the group consisting of 0, NH, S, SO and SO2; X) a compound wherein Y is C, R 7 , R 8 , R 9 , and R 10 are each hydrogen; and R 1 and R 2 form an epoxide; Y) R 10 is hydrogen; and Z ) R 3 is methyl
  • Examples of some preferred compounds of this invention include, but are in no way limited to:
  • Ar is phenyl, R 1 and R 2 taken together form a three membered epoxide ring, R 3 is methyl, R 4 and R 5 are taken together to form a double bond, R 6 is a chloro- methoxybenzyl, R 10 is hydrogen, and the remaining variables are as illustrated in the following table:
  • NCH 3 isobutyl hydrogen hydrogen benzyl
  • NCH 3 isobutyl hydrogen methyl benzyl
  • the present invention provides a method of alleviating a pathological condition caused by hyperproliferating mammalian cells comprising administering to a subject an -In ⁇
  • the method further comprises administering to the subject at least one additional therapy directed to alleviating the pathological condition.
  • the pathological condition is characterized by the formation of neoplasms.
  • the neoplasms are selected from the group consisting of mammary, small- cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS) , ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes pancreatic and esophageal, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin' s disease and Hodgkin's disease neoplasms.
  • CNS central nervous system
  • neoplastic refers to a neoplasm, which is an abnormal growth, such growth occurring because of a proliferation of cells not subject to the usual limitations of growth.
  • anti-neoplastic agent is any compound, composition, admixture, co-mixture, or blend which inhibits, ele inates, retards, or reverses the neoplastic phenotype of a cell.
  • Anti-mitotic agents or poisins may be classified into three groups on the basis of their molecular mechanism of action. The first group consists of agents, including colchicine and colcemid, which inhibit the formation of microtubules by sequestering tubulin.
  • the second group consists of agents, including vinblastine and vincristine, which induce the formation of paracrystalline aggregates of tubulin.
  • Vinblastine and vincristine are well known anticancer drugs: their action of disrupting mitotic spindle microtubules preferentially inhibits hyperproliferative cells.
  • the third group consists of agents, including taxol, which promote the polymerization of tubulin and thus stabilizes microtubules.
  • compositions can also be provided together with physiologically tolerable liquid, gel, or solid carriers, diluents, adjuvants and excipients.
  • physiologically tolerable liquid, gel, or solid carriers diluents, adjuvants and excipients.
  • Such carriers, adjuvants, and excipients may be found in the U.S . Pharmacopeia, Vol. XXII and National Formulary vol XVII, U.S. Pharmacopeia Convention, Inc. Rockville, MD (1989) . Additional modes of treatment are provided in AHFS Drug Information, 1993 e. by the American Hospital Formulary Service, pp. 522-660. Each of these references are well known and readily available to the skilled artisan.
  • the pharmaceutical composition used to treat neoplastic disease contains at least one compound of Formula I and at least one additional anti-neoplastic agent.
  • Anti-neoplastic agents which may be utilized in combination with Formula I or Formula III compounds include those provided in the Merck Index 11, pp 16-17, Merck & Co., Inc. (1989). The Merck Index is widely recognized and readily available to the skilled artisan.
  • antineoplastic agents may be antimetabolites which may include but are in no way limited to those selected from the group consisting of methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine, arabinoside, hydroxyurea, and 2- chlorodeoxyadenosine .
  • the anti-neoplastic agents contemplated are alkylating agents which may include but are in no way limited to those selected from the group consisting of cyclophosphamide, mephalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard.
  • the anti-neoplastic agents are plant alkaloids which may include but are in no way limited to those selected from the group consisting of vincristine, vinblastine, taxol, and etoposide.
  • the anti-neoplastic agents contemplated are antibiotics which may include, but are in no way limited to those selected from the group consisting of doxorubicin, daunorubicin, mitomycin C, and bleomycin.
  • the anti-neoplastic agents contemplated are hormones which may include, but are in no way limited to those selected from the group consisting of calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane.
  • the anti-neoplastic agents contemplated include enzymes which may include, but are in no way limited to those selected from the group consisting of L-Asparginase and aminoacridine derivatives such as, but not limited to, amsacrine.
  • Additional anti- neoplastic agents include those provided by Skeel, Roland T., "Antineoplastic Drugs and Biologic Response Modifier: Classification, Use and Toxicity of Clinically Useful Agents" Handbook of Cancer Chemotherapy (3rd ed.), Little Brown & Co. (1991) .
  • compositions can be administered to mammals for veterinary use.
  • domestic animals can be treated in much the same way as a human clinical patient.
  • the dosage required for therapeutic effect will vary according to the type of use, mode of administration, as well as the particularized requirements of the individual hosts. Typically, dosages will range from about 0.001 to 1000 mg/kg, and more usually 0.01 to 10 mg/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits are obtained.
  • drug dosage as well as route of administration, must be selected on the basis of relative effectiveness, relative toxicity, growth characteristics of tumor and effect of Formula I or Formula III compound on cell cycle, drug pharmacokinetics, age, sex, physical condition of the patient and prior treatment.
  • the compound of Formula I or Formula III, with or without additional anti-neoplastic agents, may be formulated into therapeutic compositions as natural or salt forms.
  • Pharmaceutically acceptable non-toxic salts include base addition salts which may be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as for example, hydrochloric or phosphoric acids or organic acids such as acetic, oxalic, tartaric, mandelic, and the like.
  • compositions may be formulated for oral administration. Such compositions are typically prepared as liquid solution or suspensions or in solid forms. Oral formulation usually include such additives as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained relsease formulations, or powders, and typically contain 1% to 95% of active ingedient. More preferably, the composition contains from about 2% to about 70% active ingredient.
  • compositions of the present invention may be prepared as injectables, either as liquid solutions, suspensions, or emulsions; solid forms suitable for solution in or suspension in liquid prior to injection.
  • injectables may be administered subcutaneously, intravenously, intraperitoneally, intramuscularly, intrathecally, or intrapleurally.
  • the active ingredient or ingredients are often mixed with diluents, carriers, or excipients which are physiologically tolerable and compatible with the active ingredient (s) .
  • Suitable diluents and excipients are for example, water, saline, dextrose, glycerol, or the like and combinations thereof.
  • the compositions may contain minor amounts of auxilary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
  • the invention further provides methods for using Formula I compounds to inhibit the proliferation of mammalian cells by contacting these cells with a Formula I compound in an amount sufficient to inhibit the proliferation of the mammalian cell.
  • a preferred embodiment is a method to inhibit the proliferation of hyperproliferative mammalian cells.
  • hyperproliferative mammalian cells are mammalian cells which are not subject to the characteristic limitations of growth (programmed cell death for example) .
  • a further preferred embodiment is when the mammalian cell is human.
  • the invention further provides contacting the mammalian cell with at least one Formula I or Formula III compound and at least one anti-neoplastic agent. The types of anti-neoplastic agents contemplated are discussed supra .
  • the invention further provides methods for using a compound of Formula I to inhibit the proliferation of hyperproliferative cells with drug-resistant phenotypes, including those with multiple drug-resistant phenotypes, by contacting said cell with a compound of Formula I in an amount sufficient to inhibit the proliferation of a hyperproliferative mammalian cell.
  • a preferred embodiment is when the mammalian cell is human.
  • the invention further provides contacting a Formula I compound and at least one additional anti-neoplastic agent, discussed supra .
  • the invention provides a method for alleviating pathological conditions caused by hyperproliferating mammalian cells for example, neoplasia, by administering to a subject an effective amount of a pharmaceutical composition containing Formula I or Formula III compound to inhibit the proliferation of the hyperproliferating cells.
  • pathological condition refers to any pathology arising from the proliferation of mammalian cells that are not subject to the normal limitations of growth. Such proliferation of cells may be due to neoplasms as discussed supra .
  • the neoplastic cells are human.
  • the present invention provides methods of alleviating such pathological conditions utilizing a compound of Formula I in combination with other therapies, as well as other anti-neoplastic agents.
  • the effectiveness of the claimed compounds can be assessed using standard methods known to the skilled artisan.
  • the compounds are screened for minimum inhibitory concentrations against KB, a human nasopharyngeal carcinoma cell line, LoVo, a human colorectal adenocarcinoma cell line.
  • the Corbett assay see Corbett, T.H. et al. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp 35-87, Kluwer Academic Publishers: Norwell, 1992. see also, Valeriote, et al. Discovery and Development of Anticancer Agents; Kluwer Academic Publishers, Norwell, 1993.
  • the most active compounds are further evaluated for cytotoxicity against four different cell types, for example a murine leukemia, a murine solid tumor, a human solid tumor, and a low malignancy fibroblast using the Corbett assay.
  • the compounds are further evaluated against a broad spectrum of murine and human tumors implanted in mice, including drug resistant tumors.
  • Tumor burden (mean tumor burden in treated animals verses mena tumor burden in untreated animals) are used as a further assessment. T/C values that are less than 42% are considered to be active by National Cancer Institute Standards; T/C values less than 10% are considered to have excellent activity and potential clinical activity by National Cancer Institute standards.
  • Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, substituted aromatic, unsubstituted heteroaromatic, and substituted heteroaromatic group;
  • R 1 is selected from the group consisting of halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, and phosphate;
  • R 2 is OH or SH; or R 1 and R 2 may be taken together with Ci ⁇ and Cig to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, or monoalkylphosphate ring; or R 1 and R 2 may be taken together to form a second bond between Ci ⁇ and C 19 ;
  • R 3 is a lower alkyl group;
  • R 4 is H or H 2 ;
  • R 5 is H or H 2 ;
  • R 4 and R 5 may be taken together to form a second bond between C 13 and C 1 4;
  • R 6 is selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, and dihaloalkoxybenzyl group;
  • R 7 is H or a lower alkyl group
  • R 8 is H or a lower alkyl group
  • R 7 and R 8 may optionally be taken together to form a cyclopropyl ring
  • R 9 is selected from the group consisting of H, a lower alkyl group, (C 1 -C 3 ) alkylaryl, and aryl
  • R 10 is selected from the group consisting of H, a lower alkyl group, (C 1 -C 3 ) alkylaryl, and aryl;
  • X is 0, NH or alkylamino; or a pharmaceutically acceptable salt or solvate thereof.
  • the cryptophycin A-B trichloroethyl ester can be prepared using information known in the literature; however, the following method is provided for the convenience of the artisan:
  • 4b 4b was prepared according to the method for the preparation of 4a. Mass Spec. (FD + ) m/e 623 (M + ) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel cryptophycin compounds which can be useful for disrupting the microtubulin system, as antineoplastic agents, and for the treatment of cancer. The invention further provides a formulation for administering the novel cryptophycin compounds.

Description

Title
TRIPEPTIDE AND TETRAPEPΗDE PHARMACEUTICAL COMPOUNDS
Field Of The Invention
This invention relates to novel cryptophycin compounds useful as anti-microtubule agents.
Background Of The Invention Neoplastic diseases, characterized by the proliferation of cells not subject to the normal control of cell growth, are a major cause of death in humans and other mammals. Clinical experience in cancer chemotherapy has demonstrated that new and more effective drugs are desirable to treat these diseases. Such clinical experience has also demonstrated that drugs which disrupt the microtubule system of the cytoskeleton can be effective in inhibiting the proliferation of neoplastic cells.
The presently claimed compounds, having an amide substitution in the cryptophycin ring, have surprisingly potent antimicrotuble activity while further having especially desired solubility properties. The compounds claimed herein address the need for compounds having acceptable solubility while retaining the desired antimicrotuble activity.
Further, such agents having the ability to disrupt the microtubule system can be useful for research purposes.
The compounds claimed herein can be prepared using total synthetic methods and are therefore well suited for development as pharmaceutically useful agents. Summary Of The Invention
The presently claimed invention provides novel cryptophycin compounds of Formula I
wherein
Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, substituted aromatic, unsubstituted heteroaromatic, and substituted heteroaromatic group;
R1 is selected from the group consisting of halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, and phosphate; R2 is OH or SH; or
R1 and R2 may be taken together with Ciβ and Cig to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, or monoalkylphosphate ring; or R1 and R2 may be taken together to form a second bond between Ciβ and Cig;
R3 is a lower alkyl group; R4 is H or H2; R5 is H or H2;
R4 and R5 may be taken together to form a second bond between C13 and C14;
R6 is selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, and dihaloalkoxybenzyl group; R7 is H or a lower alkyl group; R8 is H or a lower alkyl group; or
R7 and R8 may optionally be taken together to form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, (C1-C3) alkylaryl, and aryl;
R10 is selected from the group consisting of H, a lower alkyl group, (C1-C3) alkylaryl, and aryl; R11 is selected from the group consisting of hydrogen, simple alkyl, OH, phenyl, substituted phenyl, benzyl, and substituted benzyl;
X is 0, NH or alkylamino; or a pharmaceutically acceptable salt or solvate thereof.
The present invention provides pharmaceutical formulations, a method for disrupting a microtubulin system using an effective amount of a compound of Formula I, a method for inhibiting the proliferation of mammalian cells comprising administering an effective amount of a compound of Formula I, and a method for treating neoplasia in a mammal comprising administering an effective amount of a compound of Formula I.
Detailed Description of the Invention
As used herein, the term "simple alkyl" shall refer to C1-C7 alkyl wherein the alkyl may be saturated, unsaturated, branched, or straight chain. Examples include, but are in no way limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, propenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, methylated pentyl groups and the like.
As used herein, the term "substituted phenyl" shall refer to a phenyl group with from one to three non- hydrocarbon substituents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I. As used herein, the term "substituted benzyl" shall refer to a benzyl group with from one to three non- hydrocarbon substitutents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I .
As used herein "Lower alkoxyl group" means any alkyl group of one to five carbon atoms bonded to an oxygen atom. As used herein "lower alkyl group" means an alkyl group of one to five carbons and includes linear and nonlinear hydrocarbon chains, including for example, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, and methylated pentyl groups. As used herein "allylically substituted alkene" means any alkene having from one to seven carbon atoms which contains an alkyl substitution on it. As used herein "epoxide ring" means a three- membered ring whose backbone consists of two carbons and an oxygen atom. As used herein, "aziridine ring" means a three-membered ring whose backbone consists of two carbon atoms and a nitrogen atom. As used herein "sulfide ring" means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom. As used herein "episulfide ring" menas a three-membered ring whos backbone consists of two carbon and a sulfur atom. As used herein "sulfate group" menas a five membered ring consisting of a carbon- carbon-oxygen-sulfur-oxygen backbone with two additional oxygen atoms connected to the sulfur atom. As used herein, "monalkylphosphate ring" means a five membered ring consisting of a carbon-carbon-oxygen-phosphorous-oxygen backbone with two additional oxygen atoms, one of which bears a lower alkyl group, connected to the phosphorous atom.
As used herein, "simple unsubstituted aromatic group" refers to common aromatic rings having 4n+2 electrons in a moncyclic conjugated system, for example, but not limited to: furyl, pyrrolyl, thienyl, pyridyl and the like, or a bicyclic conjugated system, for example but not limited to indolyl or naphthyl . As used herein "simple substituted aromatic group" refers to a phenyl group substituted with a single group selected from the group consisting of halogen and lower alkyl group. As used herein the term "aryl" means an organic radical derived from an aromatic hydrocarbon by the removal of one atom; e.g., phenyl or naphthyl . Most preferably, aryl refers to C6~Cιo aryl, wherein the aryl ring system, including any alkyl substitutions, comprises from 6 to 10 carbon atoms.
The term "C1-C3 alkylaryl" represents an (C1-C3) alkylaryl substituent wherein the alkyl group is linear, such as but not limited to, benzyl, phenethyl, 3- phenylpropyl, or phenyl- t-butyl; or branched. The alkylaryl moitety is attached to the parent nucleus via the alkyl group .
As used herein, "alkylamino" has its common meaning. Thus, the phrase refers to N-RRI wherein RRI is C1-C3 alkyl. When the alkylamino group is contained within the ring as when "X" and/or "Y" is alkylamino then such alkylamino group in the ring can be represented by the
RR' _l _ group : N
As used herein, "heteroaromatic group" refers to aromatic rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur.
As used herein, "halogen" refers to those members of the group on the periodic table historically known as halogens. Methods of halogenation include, but are not limited to, the addition of hydrogen halides, substitution at high temperature, photohalogenation, etc., and such methods are known to the skilled artisan.
As used herein, the term "crypto A-B-OCH2CCI3" or
"cryptophycin A-B-trichloroethyl ester" shall mean a group of the formula:
As used herein, the term "mammal" shall refer to the Mammalia class of higher vertebrates. The term "mammal" includes, but is not limited to, a human. The term "treating" as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established. The cryptophycin compounds claimed herein can be useful for vetrinary health purposes as well as for the treatment of a human patient. Some preferred characteristics of this invention are set forth in the following tabular form wherein the features may be independently selected to provide preferred embodiments of this invention. The invention is in no way limited to the features described below:
A) R8 is ethyl, propyl, isopropyl, butyl, isobutyl or isopentyl;
B) R7 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, or isopentyl; C) R7 is H, R8 is methyl, R3 is methyl, and X and
Y are not both 0;
D) R3 is ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or isopentyl;
E) R9 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyl;
F) R10 is methyl, ethyl, propyl, butyl, isobutyl, pentyl, or isopentyl;
G) a cryptophycin compound wherein at least one of the groups selected from the group consisting of C-3, C-6, C-7, C-10, C-16, C-17, and C-18 has R stereochemistry (numbering as set forth in claim 1 i nfra . ) ;
H) a cryptophycin compound wherein at least one of the "groups selected from the group consisting of C-3, C-6, C-7, C-10, C-16, C-17, and C-18 has S stereochemistry (numbering as set forth in claim 1 i nfra . ) ;
I) Ar is phenyl with a substituent selected from the group consisting of hydrogen, halogen, and simple alkyl;
J) a compound wherein the C-7 substituent is R configuration;
K) a compound wherein the C-7 substituent is S configuration; L) R7, R8 are each hydrogen;
M) R7 and R8 are each selected from hydrogen or
OH;
N) R11 is simple alkyl;
0) R is selected from the group consisting of methyl, ethyl, n-propyl, and phenyl;
P) R1 and R2 form an epoxide ring;
Q) both X and Y are 0;
R) R4 and R5 form a double bond;
S) R6 is substituted benzyl wherein one substituent is a halogen and one is an OR12 group wherein R12 is lower alkyl;
T) a compound of Formula I is used for disruption of a microtubulin system;
U) a compound of Formula I is used as an anti- neoplastic agent;
V) a compound of Formula I is used for the treatment of cancer in a mammal;
W) a compound wherein Y is selected from the group consisting of 0, NH, S, SO and SO2; X) a compound wherein Y is C, R7, R8, R9, and R10 are each hydrogen; and R1 and R2 form an epoxide; Y) R10 is hydrogen; and Z ) R3 is methyl
Examples of some preferred compounds of this invention include, but are in no way limited to:
wherein Ar is phenyl, R1 and R2 taken together form a three membered epoxide ring, R3 is methyl, R4 and R5 are taken together to form a double bond, R6 is a chloro- methoxybenzyl, R10 is hydrogen, and the remaining variables are as illustrated in the following table:
X R9 R7 Rβ Rll*
0 isobutyl hydrogen hydrogen hydrogen
0 isobutyl hydrogen hydrogen methyl
0 isobutyl hydrogen hydrogen benzyl
0 isobutyl hydrogen hydrogen phenyl
0 isobutyl hydrogen hydrogen p-chloro- -phenyl
0 isobutyl hydrogen hydrogen ethyl
0 isobutyl hydrogen hydrogen m-methyl- -benzyl
0 isobutyl hydrogen hydrogen p-methyl- -phenyl
0 isobutyl R7 and R8 form a hydrogen cyclo-propyl
0 isobutyl R7 and R8 form a methyl cyclo-propyl
0 benzyl R7 and R8 form a benzyl cyclo-propyl
X R9 R7 Rβ Rll*
0 benzyl hydrogen hydrogen hydrogen
0 benzyl hydrogen hydrogen methyl benzyl hydrogen hydrogen benzyl benzyl hydrogen hydrogen phenyl benzyl hydrogen hydrogen p-chloro- •phenyl benzyl hydrogen hydrogen ethyl benzyl hydrogen hydrogen m-methyl- -benzyl benzyl hydrogen hydrogen p-methyl- -phenyl benzyl R7 and R8 form a hydrogen cyclo-propyl
0 benzyl R7 and R8 form a methyl cyclo-propyl
0 isobutyl hydrogen hydrogen hydrogen
0 isobutyl hydrogen hydrogen methyl
0 isobutyl hydrogen hydrogen benzyl
0 isobutyl hydrogen hydrogen phenyl
0 isobutyl hydrogen hydrogen p-chloro- -phenyl
0 isobutyl hydrogen hydrogen ethyl
0 isobutyl hydrogen hydrogen m-methyl- -benzyl
0 isobutyl hydrogen hydrogen p-methyl- -phenyl
0 isobutyl R7 and R8 form a hydrogen cyclo-propyl
0 isobutyl R7 and R8 form a methyl cyclo-propyl
NH isobutyl hydrogen hydrogen hydrogen
NH isobutyl hydrogen hydrogen methyl
NCH3 isobutyl hydrogen hydrogen benzyl
NH isobutyl hydrogen hydrogen phenyl
NH isobutyl hydrogen hydrogen p-chloro- -phenyl
NH isobutyl hydrogen hydrogen ethyl
NH isobutyl hydrogen hydrogen m-methyl- -benzyl
NH isobutyl hydrogen hydrogen p-methyl- -phenyl
NH isobutyl R7 and R8 form a hydrogen cyclo-propyl X R9 R7 R8 Rll*
NH isobutyl R7 and R8 form a methyl cyclo-propyl
NH benzyl hydrogen hydrogen hydrogen
0 benzyl hydrogen hydrogen methyl
0 benzyl hydrogen hydrogen benzyl
0 benzyl hydrogen hydrogen phenyl
0 benzyl hydrogen hydrogen p-chloro- ■phenyl
0 benzyl hydrogen hydrogen ethyl
0 benzyl hydrogen hydrogen m-methyl- ■benzyl
0 benzyl hydrogen hydrogen p-methyl- ■phenyl
0 benzyl R7 and R8 form a hydrogen cyclo-propyl
0 benzyl R7 and R8 form a methyl cyclo-propyl
0 isobutyl methyl hydrogen hydrogen
0 isobutyl methyl hydrogen methyl
0 isobutyl methyl hydrogen benzyl
0 isobutyl methyl hydrogen phenyl
0 isobutyl methyl hydrogen p-chloro- -phenyl
0 isobutyl methyl hydrogen ethyl
0 isobutyl methyl hydrogen m-methyl- -benzyl
0 isobutyl hydrogen methyl p-methyl- -phenyl
0 isobutyl hydrogen methyl hydrogen
0 isobutyl hydrogen methyl methyl
0 benzyl methyl hydrogen benzyl
0 benzyl methyl methyl hydrogen
0 benzyl methyl hydrogen methyl
0 benzyl hydrogen methyl benzyl
0 benzyl methyl hydrogen phenyl
0 benzyl methyl hydrogen p-chloro- -phenyl
0 benzyl methyl methyl ethyl
0 benzyl methyl hydrogen m-methyl- -benzyl
0 benzyl hydrogen methyl p-methyl- -phenyl
0 benzyl methyl methyl hydrogen
0 benzyl methyl methyl methyl X R9 R7 R8 Rll*
0 isobutyl methyl hydrogen hydrogen
0 isobutyl methyl hydrogen methyl
0 isobutyl methyl hydrogen benzyl
0 isobutyl hydrogen methyl phenyl
0 isobutyl hydrogen methyl p-chloro- -phenyl
0 isobutyl methyl hydrogen ethyl
0 isobutyl hydrogen methyl m-methyl- -benzyl
0 isobutyl methyl hydrogen p-methyl- -phenyl
0 isobutyl methyl methyl hydrogen
0 isobutyl methyl methyl methyl
NH isobutyl methyl hydrogen hydrogen
NH isobutyl hydrogen methyl methyl
NCH3 isobutyl hydrogen methyl benzyl
NH isobutyl methyl hydrogen phenyl
NH isobutyl methyl hydrogen p-chloro- -phenyl
NH isobutyl methyl hydrogen ethyl
NH isobutyl methyl hydrogen m-methyl- -benzyl
NH isobutyl hydrogen methyl p-methyl- -phenyl
NH isobutyl methyl methyl hydrogen
NH isobutyl methyl methyl methyl
NH benzyl methyl hydrogen hydrogen
0 benzyl hydrogen methyl methyl
0 benzyl hydrogen methyl benzyl
0 benzyl methyl hydrogen phenyl
0 benzyl hydrogen methyl p-chloro- -phenyl
0 benzyl hydrogen methyl ethyl
0 benzyl hydrogen methyl m-methyl- -benzyl
0 benzyl hydrogen methyl p-methyl- -phenyl
0 benzyl methyl methyl hydrogen
0 benzyl methyl methyl methyl
The present invention provides a method of alleviating a pathological condition caused by hyperproliferating mammalian cells comprising administering to a subject an -In¬
effective amount of a pharmaceutical or veterinary composition disclosed herein to inhibit proliferation of the cells. In a preferred embodiment of this invention, the method further comprises administering to the subject at least one additional therapy directed to alleviating the pathological condition. In a preferred embodiment of the present invention, the pathological condition is characterized by the formation of neoplasms. In a further preferred embodiment of the present invention, the neoplasms are selected from the group consisting of mammary, small- cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS) , ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes pancreatic and esophageal, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin' s disease and Hodgkin's disease neoplasms.
As used herein "neoplastic" refers to a neoplasm, which is an abnormal growth, such growth occurring because of a proliferation of cells not subject to the usual limitations of growth. As used herein, "anti-neoplastic agent" is any compound, composition, admixture, co-mixture, or blend which inhibits, ele inates, retards, or reverses the neoplastic phenotype of a cell. Anti-mitotic agents or poisins may be classified into three groups on the basis of their molecular mechanism of action. The first group consists of agents, including colchicine and colcemid, which inhibit the formation of microtubules by sequestering tubulin. The second group consists of agents, including vinblastine and vincristine, which induce the formation of paracrystalline aggregates of tubulin. Vinblastine and vincristine are well known anticancer drugs: their action of disrupting mitotic spindle microtubules preferentially inhibits hyperproliferative cells. The third group consists of agents, including taxol, which promote the polymerization of tubulin and thus stabilizes microtubules. The exhibition of drug resistance and multiple- drug resistance phenotype by many tumor cells and the clinically proven mode of action of anti-microtubule agents against neoplastic cells necessitates the development of anti-microtubule agents cytotoxic to non-drug resistant neoplastic cells as well as cytotoxic to neoplastic cells with a drug resistant phenotype.
Chemotherapy, surgery, radiation therpy, therapy with biological response modifiers, and immunotherapy are currently used in the treatment of cancer. Each mode of therapy has specific indications which are known to those of ordinary skill in the art, and one or all may be employed in an attempt to achieve total destruction of neoplastic cells. Moreover, combination chemotherapy, chemotherapy utilizing compounds of Formula I in combination with other neoplastic agents, is also provided by the subject invention as combination therapy is generally more effective than the use of a single anti-neoplastic agent. Thus, a further aspect of the present invention provides compositions containing a therapeutically effective amount of at least one compound of Formula I, including the non-toxic addition salts thereof, which serve to provide the above recited benefits. Such compositions can also be provided together with physiologically tolerable liquid, gel, or solid carriers, diluents, adjuvants and excipients. Such carriers, adjuvants, and excipients may be found in the U.S . Pharmacopeia, Vol. XXII and National Formulary vol XVII, U.S. Pharmacopeia Convention, Inc. Rockville, MD (1989) . Additional modes of treatment are provided in AHFS Drug Information, 1993 e. by the American Hospital Formulary Service, pp. 522-660. Each of these references are well known and readily available to the skilled artisan.
The present invention further provides that the pharmaceutical composition used to treat neoplastic disease contains at least one compound of Formula I and at least one additional anti-neoplastic agent. Anti-neoplastic agents which may be utilized in combination with Formula I or Formula III compounds include those provided in the Merck Index 11, pp 16-17, Merck & Co., Inc. (1989). The Merck Index is widely recognized and readily available to the skilled artisan. In a further embodiment of this invention, antineoplastic agents may be antimetabolites which may include but are in no way limited to those selected from the group consisting of methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine, arabinoside, hydroxyurea, and 2- chlorodeoxyadenosine . In another embodiment of the present invention, the anti-neoplastic agents contemplated are alkylating agents which may include but are in no way limited to those selected from the group consisting of cyclophosphamide, mephalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard. In a further embodiment, the anti-neoplastic agents are plant alkaloids which may include but are in no way limited to those selected from the group consisting of vincristine, vinblastine, taxol, and etoposide. In a further embodiment, the anti-neoplastic agents contemplated are antibiotics which may include, but are in no way limited to those selected from the group consisting of doxorubicin, daunorubicin, mitomycin C, and bleomycin. In a further embodiment, the anti-neoplastic agents contemplated are hormones which may include, but are in no way limited to those selected from the group consisting of calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane. In a further embodiment, the anti-neoplastic agents contemplated include enzymes which may include, but are in no way limited to those selected from the group consisting of L-Asparginase and aminoacridine derivatives such as, but not limited to, amsacrine. Additional anti- neoplastic agents include those provided by Skeel, Roland T., "Antineoplastic Drugs and Biologic Response Modifier: Classification, Use and Toxicity of Clinically Useful Agents" Handbook of Cancer Chemotherapy (3rd ed.), Little Brown & Co. (1991) .
These compounds and compositions can be administered to mammals for veterinary use. For example, domestic animals can be treated in much the same way as a human clinical patient. In general, the dosage required for therapeutic effect will vary according to the type of use, mode of administration, as well as the particularized requirements of the individual hosts. Typically, dosages will range from about 0.001 to 1000 mg/kg, and more usually 0.01 to 10 mg/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits are obtained. Indeed, drug dosage, as well as route of administration, must be selected on the basis of relative effectiveness, relative toxicity, growth characteristics of tumor and effect of Formula I or Formula III compound on cell cycle, drug pharmacokinetics, age, sex, physical condition of the patient and prior treatment.
The compound of Formula I or Formula III, with or without additional anti-neoplastic agents, may be formulated into therapeutic compositions as natural or salt forms. Pharmaceutically acceptable non-toxic salts include base addition salts which may be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like. Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as for example, hydrochloric or phosphoric acids or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Additional excipients which further the invention are provided to the skilled artisan for example in the U.S. Pharmacopeia . The suitability of particular carriers for inclusion in a given therapeutic composition depends on the preferred route of administration. For example, anti¬ neoplastic compositions may be formulated for oral administration. Such compositions are typically prepared as liquid solution or suspensions or in solid forms. Oral formulation usually include such additives as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained relsease formulations, or powders, and typically contain 1% to 95% of active ingedient. More preferably, the composition contains from about 2% to about 70% active ingredient.
Compositions of the present invention may be prepared as injectables, either as liquid solutions, suspensions, or emulsions; solid forms suitable for solution in or suspension in liquid prior to injection. Such injectables may be administered subcutaneously, intravenously, intraperitoneally, intramuscularly, intrathecally, or intrapleurally. The active ingredient or ingredients are often mixed with diluents, carriers, or excipients which are physiologically tolerable and compatible with the active ingredient (s) . Suitable diluents and excipients are for example, water, saline, dextrose, glycerol, or the like and combinations thereof. In addition, if desired, the compositions may contain minor amounts of auxilary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
The invention further provides methods for using Formula I compounds to inhibit the proliferation of mammalian cells by contacting these cells with a Formula I compound in an amount sufficient to inhibit the proliferation of the mammalian cell. A preferred embodiment is a method to inhibit the proliferation of hyperproliferative mammalian cells. For purposes of this invention "hyperproliferative mammalian cells" are mammalian cells which are not subject to the characteristic limitations of growth (programmed cell death for example) . A further preferred embodiment is when the mammalian cell is human. The invention further provides contacting the mammalian cell with at least one Formula I or Formula III compound and at least one anti-neoplastic agent. The types of anti-neoplastic agents contemplated are discussed supra . The invention further provides methods for using a compound of Formula I to inhibit the proliferation of hyperproliferative cells with drug-resistant phenotypes, including those with multiple drug-resistant phenotypes, by contacting said cell with a compound of Formula I in an amount sufficient to inhibit the proliferation of a hyperproliferative mammalian cell. A preferred embodiment is when the mammalian cell is human. The invention further provides contacting a Formula I compound and at least one additional anti-neoplastic agent, discussed supra . The invention provides a method for alleviating pathological conditions caused by hyperproliferating mammalian cells for example, neoplasia, by administering to a subject an effective amount of a pharmaceutical composition containing Formula I or Formula III compound to inhibit the proliferation of the hyperproliferating cells. As used herein "pathological condition" refers to any pathology arising from the proliferation of mammalian cells that are not subject to the normal limitations of growth. Such proliferation of cells may be due to neoplasms as discussed supra .
In a further preferred embodiment the neoplastic cells are human. The present invention provides methods of alleviating such pathological conditions utilizing a compound of Formula I in combination with other therapies, as well as other anti-neoplastic agents. The effectiveness of the claimed compounds can be assessed using standard methods known to the skilled artisan.
The compounds are screened for minimum inhibitory concentrations against KB, a human nasopharyngeal carcinoma cell line, LoVo, a human colorectal adenocarcinoma cell line. The Corbett assay, see Corbett, T.H. et al. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp 35-87, Kluwer Academic Publishers: Norwell, 1992. see also, Valeriote, et al. Discovery and Development of Anticancer Agents; Kluwer Academic Publishers, Norwell, 1993.
The most active compounds are further evaluated for cytotoxicity against four different cell types, for example a murine leukemia, a murine solid tumor, a human solid tumor, and a low malignancy fibroblast using the Corbett assay.
The compounds are further evaluated against a broad spectrum of murine and human tumors implanted in mice, including drug resistant tumors.
Tumor burden (T/C) (mean tumor burden in treated animals verses mena tumor burden in untreated animals) are used as a further assessment. T/C values that are less than 42% are considered to be active by National Cancer Institute Standards; T/C values less than 10% are considered to have excellent activity and potential clinical activity by National Cancer Institute standards.
Evaluation of compounds of Formula I suggest that the compounds can be useful in the treatment methods claimed herein. Further, the compounds will be useful for disrupting the microtubule system.
The results of testing compounds of this invention using the above-described assays are as follows:
Rl R2 R7 Rβ IC50. nM
R1 and R2 Together CH3 CH3 3.0 form a double bond
R1 and R2 Together H H 0.77 form a double bond
R1 and R2 Together CH3 CH3 0.014 form an epoxide (CCRF-CEM)
R1 and R2 Together H H 0.16 form an epoxide (CCRF-CEM)
Compounds of the Formula III may be preferred:
wherein
Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, substituted aromatic, unsubstituted heteroaromatic, and substituted heteroaromatic group; R1 is selected from the group consisting of halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, and phosphate; R2 is OH or SH; or R1 and R2 may be taken together with Ciβ and Cig to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, or monoalkylphosphate ring; or R1 and R2 may be taken together to form a second bond between Ciβ and C19; R3 is a lower alkyl group; R4 is H or H2; R5 is H or H2;
R4 and R5 may be taken together to form a second bond between C13 and C14; R6 is selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, and dihaloalkoxybenzyl group;
R7 is H or a lower alkyl group; R8 is H or a lower alkyl group; or
R7 and R8 may optionally be taken together to form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, (C1-C3) alkylaryl, and aryl; R10 is selected from the group consisting of H, a lower alkyl group, (C1-C3) alkylaryl, and aryl;
X is 0, NH or alkylamino; or a pharmaceutically acceptable salt or solvate thereof.
Further preferred compounds can be those wherein R11 is Cι-C2 alkyl or benzyl. Compounds of this invention can be prepared as illustrated using the following schemes.
Scheme 1
The cryptophycin A-B trichloroethyl ester can be prepared using information known in the literature; however, the following method is provided for the convenience of the artisan:
LiOH
The artisan can utilize appropriate starting materials and reagents to prepare desired compounds using the guidance of the previous schemes and following examples.
The artisan can utilize appropriate starting materials and reagents to prepare desired compounds using the guidance of the previous schemes and following examples.
To further illustrate the invention the following examples are provided. The scope of the invention is in no way to be construed as limited to or by the following examples . PREPARATION 1
To a solution containing 100 mg (0.221 mmol) of Cryptophycin A-B trichloroethyl ester and 82 mg (0.332 mmol) of N-BOC-leucine in 5 ml of methylene chloride was added 68 mg (0.332 mmol) of dicyclohexylcarbodiimide (DCC) and 5 mg of N, N-4-dimethylaminopyridine (DMAP) . The reaction was strirred at 25°C for 30 minutes, then diluted with 50 inL of ethyl acetate. The organic solution was washed with 0.5 Ν HC1 and saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated in vacuo . The crude material was purified by flash chromatography using 25% ethyl acetate-hexane as the eluent. The major fraction was concentrated in vacuo to give 110 mg (62%) of a white amorphous solid, which was characterized as _ " . Mass Spec. (FD+) m/e 802 (M+) .
PREPARATION 2
3a
To a solution containing 92 mg (0.115 mmol) of 2 in 2 L of methylene chloride was added 2 mL of trifluoroacetic acid (TFA) . The reaction was stirred at 25°C for 1 hour and concentrated in vacuo to give 100 mg of the corresponding TFA salt, which was used without further purification. To a solution containing 53 mg (0.244 mmol) of N-BOC-2 , 2- dimethyl-b-alanine in 10 mL 50% THF-DMF was added 41 mg (0.305 mmol) of N-hydroxybenzotriazole (HOBt) and 52 mg (0.244 mmol) of l-ethyl-3- (3-dimethylaminopropyl) - carbodiimide (EDC) . The reaction was stirred at 25°C for 15 min., after which a solution containing the TFA salt and 20 mL (0.183 mmol) of N-methylmorpholine (ΝMM) in 5 L of DMF was added. The reaction was stirred at 25°C for 15 hours, diluted with 100 mL of ethyl acetate and the organic solution washed twice with 0.5 Ν HC1, twice with saturated sodium bicarbonate solution and twice with brine. The organic layer was dried over sodium sulfate and concentrated in vacuo to give 105 mg (95%) of a white amorphous solid, which was characterized as 3a. Mass Spec. (FD+) m/e 901 (M+) .
PREPARATION 3
3b
3b was prepared according to the method for the preparation of 3a. Mass Spec. (FD+) m/e 873 (M+) .
4a
To a solution of 105 mg (0.116 mmol) of 3a in 2 mL CH2CI2 was added 2 mL of trifluoroacetic acid (TFA) . The reaction was strirred at 25°C for 30 min, after which it was poured into 25 mL of a saturated aqueous sodium bicarbonate solution. An additional 25 mL of CH2CI2 was added and the organic phase was washed with IN NaOH, dried over sodium sulfate and concentrated in vacuo . This crude material was dissolved in 10 mL of toluene and stirred at 25°C as 11 mg (0.116 mmol) of 2-hydroxypyridine was added. The reaction was stirred at 25°C for 18 h. The reaction was diluted with 50 mL of ethyl acetate and the organic phase washed twice with IN HC1, twice with brine and twice with saturated sodium bicarbonate solution. The organic solution was dried over sodium sulfate and concentrated in vacuo . The crude material was purified by flash chromatography on silica gel using 50% ethyl acetate-hexane as the eluent. The major fraction was concentrated in vacuo to give 27 mg (36%) of a white amorphous solid, which was characterized as _a. Mass Spec. (FD+) m/e 651 (M+) .
4b 4b was prepared according to the method for the preparation of 4a. Mass Spec. (FD+) m/e 623 (M+) .
5a
To a solution containing 20 mg (0.031 mmol) of 4a in 5 mL of CH2CI2 was added 6.3 mg (0.037 mmol) of m- chloroperbenzoic acid (mCPBA) . The reaction was strirred at 25°C and monitored by HPLC (reverse phase, Ci8, 70% acetonitrile-water) . After about 5 h, the reaction slowed and an additional 5 mg mCPBA was added. The reaction was stirred at 25°C and after another 12 h, was complete. The reaction was diluted with 25 mL CH2CI2 and washed twice with a saturated sodium meta-bisulfite solution and twice with a saturated sodium bicarbonate solution. The organic layer was dried and concentrated in vacuo to give 18 mg (85%) of a white amorphous solid, which was charaterized as a 2:1 mixture of diastereomeric epoxides of 5a. Mass Spec. (FD+) m/e 667 (M+) .
EXAMPLE 4
5b
5b was prepared according to the method for the preparation of 5a. Mass Spec. (FD+) m/e 639 (M+) . EXAMPLE 5
A solution containing 50 mg (0.075 mmol) of 5a in 2 mL chloroform was cooled to -60°C and 47 mL (0.375 mmol) of chlorotrimethylsilane (TMSC1) was added. The reaction was warmed to 25°C and poured into 20 mL of water. An additional 20 mL of chloroform was added and the organic layer was separated, dried over sodium sulfate and concentrated in vacuo to give a mixture of chlorohydrins . The major chlorohydrin was purified by flash chromatography on silica gel using ethyl acetate as the eluent. The major fraction was concentrated in vacuo to give 19 mg (54%) of a white amorphous solid, which was characterized as _. Mass Spec. (FD+) m/e 704 (M+) .
To a solution of 5.0 mg (0.0071 mmol) of 6 in 2 mL of 50% acetonitrile: water was added 2 mg of sodium carbonate. The reaction was stirred at 25°C for 1 hour, then diluted with 10 mL ethyl acetate. The organic solution was washed once with water, dried over sodium sulfate and concentrated in vacuo to give 4.0 mg (85%) of a white amorphous solid, which was characterized as pure epoxide _ Mass Spec. (FD+ ι m/e 667 (M+) .

Claims

e Claim :
1. A compound of Formula I
wherein
Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group; R1 is halogen, SH, amino, monoalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, or phosphate;
R2 is OH or SH; or
R1 and R2 may be taken together to form a 3 member epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, or a monoalkylphosphate ring; or
R1 and R2 may be taken together to form a second bond between Ci╬▓ and C19;
R3 is a lower alkyl group; R4 is H;
R5 is H;
R4 and R5 may be taken together to form a second bond between C13 and C14;
R6 is benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkoxybenzyl group; R7 is H or a lower alkyl group; R8 is H or a lower alkyl group; or R7 and R8 may optionally be taken together to form a cyclopropyl ring; R9 is selected from the group consisting of H, a lower alkyl group, (C1-C3) alkylaryl, and aryl;
R10 is selected from the group consisting of H, a lower alkyl group, C1-C3) alkylaryl, and aryl;
R11 is selected from the group consisting of hydrogen, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
X is 0, NH or alkylamino; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound of Claim 1 wherein R11 is hydrogen.
3. A compound of Claim 2 wherein X is 0.
4. A compound of Claim 3 wherein R6 is a group of the formula:
5. A compound of Claim 4 wherein R8 and R7 are each methyl.
6. A compound of Claim 5 wherein R9 is isobutyl and R10 is hydrogen.
7. A compound of Claim 6 wherein R1 and R2 form an epoxide group.
8. A compound of Claim 6 wherein R1 is Cl and R2 is OH.
9. A compound of Claim 1 wherein X is 0.
10. A compound of Claim 9 wherein R6 is a group of the formula:
11. A compound of Claim 10 wherein R8 and R7 are each methyl .
12. A compound of Claim 11 wherein R9 is isobutyl and R10 is hydrogen.
13. A compound of Claim 12 wherein R11 is C1-C4 alkyl
14. A compound of Claim 12 wherein R11 is benzyl
15. A compound of Claim 14 wherein R1 and R2 form an epoxide group.
16. A compound of Claim 14 wherein R1 is Cl and R2 is OH.
17. A method for disrupting microtubule binding in a mammal comprising administering an effective amount of a compound of Claim 1.
18. A method for disrupting microtubule binding in vitro comprising administering an effective amount of a compound of Claim 1.
19. A method for treating a neoplasm in a mammal comprising administering an effective amount of a compound of Claim 1 to a patient in need thereof.
20. A formulation comprising a compound of Claim 1 and one or more pharmaceutically acceptable diluents or carriers therefor.
21. A compound as claimed by Claim 1 or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical .
22. A pharmaceutical formulation comprising as an active ingredient a compound of Claim 1 or a pharmaceutically acceptable salt thereof, associated with one or more excipients or carriers therefor.
EP98907625A 1997-02-26 1998-02-25 Tripeptide and tetrapeptide pharmaceutical compounds Withdrawn EP0975610A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3911597P 1997-02-26 1997-02-26
US39115P 1997-02-26
PCT/US1998/003666 WO1998038178A1 (en) 1997-02-26 1998-02-25 Tripeptide and tetrapeptide pharmaceutical compounds

Publications (2)

Publication Number Publication Date
EP0975610A1 true EP0975610A1 (en) 2000-02-02
EP0975610A4 EP0975610A4 (en) 2000-05-17

Family

ID=21903772

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98907625A Withdrawn EP0975610A4 (en) 1997-02-26 1998-02-25 Tripeptide and tetrapeptide pharmaceutical compounds

Country Status (5)

Country Link
EP (1) EP0975610A4 (en)
JP (1) JP2001513775A (en)
AU (1) AU6338698A (en)
CA (1) CA2281107A1 (en)
WO (1) WO1998038178A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932601A4 (en) * 1996-08-30 2000-02-02 Lilly Co Eli Process for preparing pharmaceutical compounds
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040184A1 (en) * 1995-03-07 1996-12-19 University Of Hawaii New cryptophycins from synthesis
WO1997007798A1 (en) * 1995-08-30 1997-03-06 Eli Lilly And Company Pharmaceutical compounds
WO1997023211A1 (en) * 1995-12-22 1997-07-03 Eli Lilly And Company Pharmaceutical compounds
WO1998008506A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds
WO1998008505A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
US5254682A (en) * 1989-12-08 1993-10-19 Merck & Co., Inc. Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
US5225528A (en) * 1990-02-27 1993-07-06 Merck & Co., Inc. Cyclic hexapeptide oxytocin antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040184A1 (en) * 1995-03-07 1996-12-19 University Of Hawaii New cryptophycins from synthesis
WO1997007798A1 (en) * 1995-08-30 1997-03-06 Eli Lilly And Company Pharmaceutical compounds
WO1997023211A1 (en) * 1995-12-22 1997-07-03 Eli Lilly And Company Pharmaceutical compounds
WO1998008506A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds
WO1998008505A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOISO, YUKIKO ET AL: "Effects of arenastatin A and its synthetic analogs on microtubule assembly" CHEM.-BIOL. INTERACT. (1996), 102(3), 183-191,1996, XP000872569 *
See also references of WO9838178A1 *

Also Published As

Publication number Publication date
CA2281107A1 (en) 1998-09-03
AU6338698A (en) 1998-09-18
JP2001513775A (en) 2001-09-04
WO1998038178A1 (en) 1998-09-03
EP0975610A4 (en) 2000-05-17

Similar Documents

Publication Publication Date Title
EP3388427B1 (en) Derivatives of dolastatin 10 and auristatins
KR100459527B1 (en) Synthetic New Cryptopycin
EP0830136B1 (en) New cryptophycins from synthesis
EP0792875B1 (en) Cryptophycin derivatives and their use as anti-microtubule agents
EP0869786B1 (en) Pharmaceutical compounds
WO1998008506A1 (en) Pharmaceutical compounds
EP0975610A1 (en) Tripeptide and tetrapeptide pharmaceutical compounds
FI84355C (en) PREPARATION OF THERAPEUTIC SUBSTANCES FOR THERAPEUTIC ACTION 5 - (3-ELLER 4-KINUCLIDINYL) THIOMETHYL SUBSTITUTES PRISTINOMYCIN AND ELLER VIRGINAMYSIN S-DERIVAT.
IE57990B1 (en) Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines
WO2012158933A9 (en) Macrocycllc therapeutic agents and methods of treatment
CA2264297A1 (en) Pharmaceutical compounds
US20020128185A1 (en) Pharmaceutical compounds
CA2245932A1 (en) Pharmaceutical compounds
JP5462494B2 (en) Cyclic depsipeptide
DK2699580T3 (en) DIAZONAMI DISEASES
ZA200200312B (en) Streptogramin derivatives, production thereof and compositions containing the same.
JPH03170427A (en) Treatment of multiple drug resisting tumor with pyridinyloxazole-2-one
RU2195458C2 (en) Cryptoficine compound, pharmaceutical composition, method of inhibition of cell proliferation and method of pathological state relief
PT792875E (en) DERIVATIVES OF CRYPTOPHICINE AND ITS USE AS ANTI-MICROTUBLE AGENTS
CA2214565C (en) New cryptophycins from synthesis
JP2004512256A (en) Streptogramin derivatives, their preparation and compositions containing them
JP2001122780A (en) Anti-malignant tumor agent
MXPA98001604A (en) Farmaceuti compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990810;LT PAYMENT 19990819;LV PAYMENT 19990819;RO PAYMENT 19990819;SI PAYMENT 19990819

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 273/00 A, 7C 07D 413/06 B, 7A 61K 31/395 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000330

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020326